80407-64-3

Basic information

• Product Name: 3,4-bis(2-Methoxyethoxy)benzaldehyde
• Synonyms: 3,4-bis(2-Methoxyethoxy)benzaldehyde;Erlotinib Impurity 33
• CAS NO: 80407-64-3
• Molecular Formula: C₁₃H₁₈O₅
• Molecular Weight: 254.27902
• EINECS: 1308068-626-2
• Mol File: 80407-64-3.mol

Chemical Properties

• Boiling Point: 380.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.115±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3,4-bis(2-Methoxyethoxy)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-bis(2-Methoxyethoxy)benzaldehyde(80407-64-3)
• EPA Substance Registry System: 3,4-bis(2-Methoxyethoxy)benzaldehyde(80407-64-3)

Safety Data

• Hazardous Substances Data: 80407-64-3(Hazardous Substances Data)

Usage

Uses

Used in Polymer Production:
3,4-bis(2-Methoxyethoxy)benzaldehyde is used as a building block for the creation of various polymer materials. Its chemical structure allows it to be incorporated into the synthesis process, contributing to the formation of polymers with specific properties and applications.
Used in Chemical Synthesis:
3,4-bis(2-Methoxyethoxy)benzaldehyde is used as a reactive intermediate in chemical synthesis. Its presence in the reaction mixture can lead to the formation of new compounds with different functional groups or structural features, expanding the range of possible applications for the resulting products.
Used in Research and Development:
3,4-bis(2-Methoxyethoxy)benzaldehyde is utilized in research and development settings to explore its potential applications and properties. Scientists and chemists may investigate its reactivity, stability, and compatibility with other compounds, as well as its potential use in the creation of new materials or products.

Upstream product

• 627-42-9 2-chloroethyl methyl ether 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 36865-41-5 3-bromopropanol methyl ether 
• 4296-15-5 2-iodo-1-methoxyethane 
• 121-33-5 vanillin 

Downstream Products

• 1006377-63-4 C₁₃H₁₉NO₅ 
• 1175086-56-2 3,4-bis-(2-methoxy-ethoxy)-benzylamine 
• 1387641-12-4 3-{[6,7-Bis-(2-methoxy-ethoxy)-2-oxo-1,2-dihydro-quinoline-3-carbonyl]-amino}-4-methyl-benzoic acid methyl ester 
• 819813-71-3 3,4-bis(2-methoxyethoxy)-benzoic acid 
• 179688-14-3 methyl 3,4-bis{[2-(methyloxy)ethyl]oxy}benzoate 
• 501684-22-6 methyl 4,5-bis(2-methoxyethoxy)-2-nitrobenzoate 
• 476168-17-9 2-amino-4,5-bis-(2-methoxyethoxy)-benzoic acid methyl ester 
• 236750-62-2 2-amino-4,5-bis[(2-methoxy)ethoxy]benzamide 
• 1172625-04-5 4,5-bis(2-methoxyethoxy)-2-nitrobenzamide 
• 1384975-87-4 4,5-bis-(2-methoxy-ethoxy)-2-nitro-benzaldehyde 
• 183319-69-9 erlotinib hydrochloride 
• 183322-18-1 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline 
• 236750-65-5 4,5-bis(2-methoxyethoxy)-2-nitrobenzonitrile 
• 80407-68-7 3,4-bis(2-methoxyethoxy)-benzonitrile 

Relevant articles and documents

The influence of polyether substituents on biological activity of curcumin derivatives

Curcumin is reported as an anti-proliferative and chemopreventive compound. However, it shows poor water solubility, low bioavailability, and rapid metabolism. To address these problems, curcumin derivatives substituted with polyether chain were synthesiz

Styryl xanthine derivatives and uses thereof (by machine translation)

The invention discloses styryl xanthine derivatives and application, and particularly, relates to a novel styryl xanthine derivative and a pharmaceutical composition containing the same, and can be used as selective adenosine A. 2A Are antagoni

Preparation method of erlotinib hydrochloride intermediate

The invention provides a preparation method of an erlotinib hydrochloride intermediate. The preparation method comprises following steps: removing the methyl of vanillin, performing esterification, converting an aldehyde group into a nitrile group, and carrying out nitration, reduction, hydrolysis, and ring forming reactions. The reaction route is represented in the description. The technology isreasonable, the operation is simple, the cost is low, and the reaction yield is high.

Preparation method of erlotinib intermediate

The invention relates to a preparation method of an erlotinib intermediate. The method concretely comprises the following steps: 1, dissolving vanillin in an organic solvent I, adding aluminum trichloride, adding pyridine in a dropwise manner, and reacting to obtain ELTA; 2, dissolving the ELTA in an organic solvent II, adding 2-chloroethylmethyl ether, potassium carbonate and a phase transfer catalyst, and reacting to obtain ELTB; 3, adding the ELTB to water, adding an alkali and potassium permanganate, and reacting to obtain ELTC; 4, adding concentrated sulfuric acid to methanol in a dropwise manner, adding the ELTC to the above reaction system, and reacting to obtain ELTD; 5, adding concentrated sulfuric acid to concentrated nitric acid in a dropwise manner, dissolving the ELTD in an organic solvent IV, adding a prepared mixed acid to the reaction system, and reacting to obtain ELTE; 6, adding the ELTE, iron powder and ammonium chloride to an organic solvent V, adding concentrated hydrochloric acid in a dropwise manner, and reacting to obtain ELTF; and 7, adding the ELTF, trimethyl orthoformate and ammonium acetate to an organic solvent VI, and reacting to obtain the erlotinib intermediate.

CARBOXYLIC ACID ARYL AMIDES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer.

NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS

The invention relates to substituted pyrazolo[3,4-d]pyrimidine derivatives of the Formula-(I), or pharmaceutically acceptable salts thereof, which possess anti-proliferative activity such as anti-cancer activity and are accordingly useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of substituted pyrazolo[3,4-d]pyrimidine derivatives, to pharmaceutical compositions containing the compound and to its use in the manufacture of medicaments for the production of an anti-proliferative effect in a warm-blooded animal such as man

ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER

Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

A Comparison of the Inhibitory Action of 5-(Substituted-benzyl)-2,4-diaminopyrimidines on Dihydrofolate Reductase from Chicken Liver with That from Bovine Liver

Forty-four 5-(substituted-benzyl)-2,4-diaminopyrimidines have been tested as inhibitors of chicken and bovine liver dihydrofolate reductase.The chicken enzyme is, on the average, about 10 times less easily inhibited than bovine enzyme.Substituents which show the greatest selectivity are 4-NHCOCH3, 3-OC4H9, 3-I, 3-CF3-4-OCH3, and 3,4,5-(OCH3)3.The inhibition constants have been used to formulate quantitative structure-activity relationships for comparative purposes.